Next Article in Journal
Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11
Previous Article in Journal
Applicability of Traditional In Vitro Toxicity Tests for Assessing Adverse Effects of Monoclonal Antibodies: A Case Study of Rituximab and Trastuzumab
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibodies
Volume 7
Issue 3
10.3390/antib7030031
antibodies-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Antibodies 2017, 6(4), 15.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Moeker, N.; et al. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. Antibodies 2017, 6, 15

by
Nina Möker
1,
Solveig Peters
1,
Robert Rauchenberger
1,
Nicolae Ghinea
2,
Christian Kunz
1 and
Antibodies Editorial Office
3,*
1
MorphoSys AG, Discovery Alliance and Technologies, 82152 Planegg, Bavaria, Germany
2
Curie Institute, Inserm-Tumoral Angiogenesis Unit, Translational Research Department, Curie Hospital, 75005-Paris, France
3
MDPI, St. Alban-Anlage 66, 4052 Basel, Switzerland
*
Author to whom correspondence should be addressed.
Antibodies 2018, 7(3), 31; https://doi.org/10.3390/antib7030031
Submission received: 20 August 2018 / Accepted: 22 August 2018 / Published: 24 August 2018
Versions Notes
The authors wish to make the following correction to the Conflict of Interests section in their published paper [1]:
“Christian Kunz and Solveig Peters are employees and Nina Möker and Robert Rauchenberger are former employees of MorphoSys AG, which owns the Ylanthia antibodies described in the publication.”
The manuscript will be updated and the original will remain online on the article webpage.

Reference

  1. Moeker, N.; Peters, S.; Rauchenberger, R.; Ghinea, N.; Kunz, C. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. Antibodies 2017, 6, 15. [Google Scholar] [CrossRef]

Share and Cite

MDPI and ACS Style

Möker, N.; Peters, S.; Rauchenberger, R.; Ghinea, N.; Kunz, C.; Antibodies Editorial Office. Correction: Moeker, N.; et al. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. Antibodies 2017, 6, 15. Antibodies 2018, 7, 31. https://doi.org/10.3390/antib7030031

AMA Style

Möker N, Peters S, Rauchenberger R, Ghinea N, Kunz C, Antibodies Editorial Office. Correction: Moeker, N.; et al. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. Antibodies 2017, 6, 15. Antibodies. 2018; 7(3):31. https://doi.org/10.3390/antib7030031

Chicago/Turabian Style

Möker, Nina, Solveig Peters, Robert Rauchenberger, Nicolae Ghinea, Christian Kunz, and Antibodies Editorial Office. 2018. "Correction: Moeker, N.; et al. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. Antibodies 2017, 6, 15" Antibodies 7, no. 3: 31. https://doi.org/10.3390/antib7030031

APA Style

Möker, N., Peters, S., Rauchenberger, R., Ghinea, N., Kunz, C., & Antibodies Editorial Office. (2018). Correction: Moeker, N.; et al. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. Antibodies 2017, 6, 15. Antibodies, 7(3), 31. https://doi.org/10.3390/antib7030031

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop